Regencell Bioscience Launches $500 Million At-the-Market Share Offering Program

An update from Regencell Bioscience ( (RGC) ) is now available.

On March 30, 2026, Hong Kong-based Regencell Bioscience Holdings Limited said it has established an at-the-market equity offering program, under which it may issue and sell up to $500 million of its ordinary shares on Nasdaq or through other permitted methods. The company has appointed Univest Securities, LLC as sales agent, giving it flexible, discretionary access to capital that can be tapped as market conditions allow.

Regencell is not obligated to sell any shares under the program, and sales, if executed, will occur at prevailing market prices or prices linked to them. The proceeds are earmarked primarily for working capital, capital expenditures and general corporate purposes, a move that could bolster its balance sheet and fund ongoing development in its niche neurological treatment franchise.

More about Regencell Bioscience

Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on researching, developing and commercializing Traditional Chinese Medicine-based treatments for neurocognitive disorders and degeneration. Its primary focus is on natural and holistic therapies for Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder, with the stated ambition of becoming a global market leader in neurological disorder treatments.

Average Trading Volume: 416,048

Technical Sentiment Signal: Buy

Current Market Cap: $12.69B

See more insights into RGC stock on TipRanks’ Stock Analysis page.